BioMed Alliance response to the European Medicines Agency’s public consultation: Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

The European Medicines Agency has released for public consultation a draft guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. 

More info here

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.